RxDoctor Payments Data

Roberto Mera-Lastra, MD

Gastroenterology · Rio Grande, PRNPI 1407812381

Payments from drug & device makers

$2,535in general payments, 2019–2025

Across 43 payments — averaging $58.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • E.r. Squibb & Sons, L.L.C.$699
  • Johnson & Johnson$339
  • Boston Scientific$205
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • Apollo Endosurgery US Inc$32
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$2,49999%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,535 in reported general payments places this provider in the 60th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$12,758
Medicare patients
25
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$324,809
Humira(Cf) PenAdalimumab22$152,848
SuprepSodium, Potassium,mag Sulfates550$64,898
SutabSod Sulf/Pot Chloride/Mag Sulf254$41,983
Mesalamine35$22,442
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates203$16,747
Mesalamine DrMesalamine17$10,592
Omeprazole675$3,853
Clarithromycin79$2,927
Sucralfate53$2,800
ClenpiqSod Picosulf/Mag Ox/Citric Ac14$2,440
Meperidine HclMeperidine Hcl/Pf386$1,703
Tetracycline Hcl12$1,686
Amoxicillin68$1,242
Midazolam HclMidazolam Hcl/Pf394$1,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$339$324,80912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Rio Grande

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →